LIGAND PHARMACEUTICALS INCORPORATED Cost of Revenue
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Cost of Revenue of $3.15 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2019-11-08
- LIGAND PHARMACEUTICALS INCORPORATED cost of goods and services sold for the quarter ending 2019-09-30 was $3.15M, a 115.55% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED cost of goods and services sold for the quarter ending 2019-06-30 was $2.40M, a 112.08% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED cost of goods and services sold for the quarter ending 2019-03-31 was $3.86M, a 389.59% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED cost of goods and services sold for the quarter ending 2018-12-31 was $2.96M, a 70.02% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED cost of goods and services sold for fiscal 2018 was $6.34M, a 18.10% increase from fiscal 2017.
- LIGAND PHARMACEUTICALS INCORPORATED cost of goods and services sold for fiscal 2017 was $5.37M, a 3.68% decline from fiscal 2016.
- LIGAND PHARMACEUTICALS INCORPORATED cost of goods and services sold for fiscal 2016 was $5.57M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2019-09-30 | $3.15M 10-Q · filed 2019-11-08 | $5.55M derived: sum of 2 quarters · filed 2019-11-08 | $9.41M 10-Q · filed 2019-11-08 | $12.37M derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-06-30 | $2.40M 10-Q · filed 2019-08-08 | $6.26M 10-Q · filed 2019-08-08 | $9.22M derived: sum of 3 quarters · filed 2019-08-08 | $10.68M derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-03-31 | $3.86M 10-Q · filed 2019-05-09 | $6.81M derived: sum of 2 quarters · filed 2019-05-09 | $8.27M derived: sum of 3 quarters · filed 2019-11-08 | $9.41M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $4.42M derived: sum of 2 quarters · filed 2019-11-08 | $5.55M derived: sum of 3 quarters · filed 2019-11-08 | $6.34M 10-K · filed 2019-02-28 |
| 2018-09-30 | $1.46M 10-Q · filed 2019-11-08 | $2.59M derived: sum of 2 quarters · filed 2019-11-08 | $3.38M 10-Q · filed 2019-11-08 | $5.12M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $1.13M 10-Q · filed 2019-08-08 | $1.92M 10-Q · filed 2019-08-08 | $3.66M derived: sum of 3 quarters · filed 2019-08-08 | $6.04M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $788.00K 10-Q · filed 2019-05-09 | $2.53M derived: sum of 2 quarters · filed 2019-05-09 | $4.91M derived: sum of 3 quarters · filed 2019-05-09 | $5.81M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $4.12M derived: sum of 2 quarters · filed 2019-02-28 | $5.03M derived: sum of 3 quarters · filed 2019-02-28 | $5.37M 10-K · filed 2019-02-28 |
| 2017-09-30 | $2.38M 10-Q · filed 2018-11-08 | $3.29M derived: sum of 2 quarters · filed 2018-11-08 | $3.63M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $903.00K 10-Q · filed 2018-08-08 | $1.24M 10-Q · filed 2018-08-08 | ||
| 2016-12-31 | $5.57M 10-K · filed 2019-02-28 |